Table 3.
Number (%) of hrHPV types in cervical samples at study entry in the total vaccinated cohort and in hrHPV positive women
| Total vaccinated cohort | hrHPV positive women | ||
|---|---|---|---|
| n | % | % | |
| All regions | N = 6,0351 | N = 924 | |
| Any hrHPV | 924 | 15.3 | 100 |
| 1 type | 699 | 11.6 | 75.6 |
| Multiple types | 225 | 3.7 | 24.4 |
| 2 types | 171 | 2.8 | 18.5 |
| 3 types | 38 | 0.6 | 4.1 |
| 4 types | 11 | 0.2 | 1.2 |
| 5 types | 4 | 0.1 | 0.4 |
| 6 types | 1 | 0 | 0.1 |
| Urban2 | N = 1,683 | N = 301 | |
| Any hrHPV | 301 | 17.9 | 100 |
| 1 type | 222 | 13.2 | 73.8 |
| Multiple types | 79 | 4.7 | 26.2 |
| Rural3 | N = 4352 | N = 623 | |
| Any hrHPV | 623 | 14.3 | 100 |
| 1 type | 477 | 11.0 | 76.6 |
| Multiple types | 146 | 3.4 | 23.4 |
1
Baseline data were not available for 16 participants due to unsatisfactory cervical samples.
2
Subjects enrolled at Xuzhou CDC.
3
Subjects enrolled at Binhai CDC, Jintan CDC and Lianshui CDC.
hrHPV, high-risk human papillomavirus DNA positive; N, number of subjects with available results; n, number of subjects in given category; %, n/N × 100.